.png)
In this episode, Chris Nelson, a Chief Scientific Officer at nCode Bio, discusses his journey from blood transfusion testing and cancer genomics to mRNA sequence design. He explores how AI can advance mRNA therapeutics, why mRNA modeling remains challenging, and how nCode Bio is approaching the problem differently.
A strategic partnership combining nCode's AI-driven mRNA sequence optimization with SyVento's GMP manufacturing, LNP formulation and sterile fill & finish.
SyVento BioTech is pleased to announce a strategic partnership with nCode, a company specializing in AI-driven mRNA sequence optimization and computational design. Together, we offer biotech and pharmaceutical innovators a more integrated development pathway, from optimized mRNA/LNP design to clinical-ready drug product manufacturing.
The partnership combines two highly specialized capabilities essential for successful mRNA/LNP therapeutic development.
nCode provides AI-powered mRNA sequence optimization, helping improve construct performance, stability and targeted delivery.
SyVento BioTech delivers end-to-end CDMO services, including GMP mRNA Drug Substance manufacturing, lipid nanoparticle (LNP) and liposome development, sterile Fill & Finish, analytical method development and quality testing for preclinical and clinical-stage programs.
As part of the collaboration, nCode becomes SyVento's preferred partner for mRNA sequence optimization, while SyVento becomes nCode's preferred partner for GMP manufacturing, LNP formulation and sterile Fill & Finish.
Developing RNA therapeutics often requires coordinating multiple specialized partners. Every handover between companies can introduce additional complexity, extend timelines and increase technology transfer risks.
By combining complementary expertise, SyVento BioTech and nCode enable developers to:
The result is a more efficient and coordinated development process, helping innovators advance promising mRNA/LNP candidates toward clinical evaluation with greater confidence.
As RNA therapeutics continue to reshape modern medicine, successful programs depend on both intelligent molecule design and robust manufacturing capabilities. Through this strategic partnership, SyVento BioTech and nCode provide an integrated solution that helps developers move promising therapies from concept to clinic more efficiently while maintaining the high-quality standards required for clinical development.
SyVento BioTech is a European CDMO specializing in the development and GMP manufacturing of advanced RNA therapeutics and lipid-based drug delivery systems. The company provides integrated services spanning mRNA Drug Substance manufacturing, LNP and liposome formulation development, sterile Fill & Finish, analytical development and quality testing for preclinical and clinical-stage programs. By combining scientific expertise with flexible project execution, SyVento BioTech enables biotechnology and pharmaceutical companies to efficiently progress RNA therapeutic programs toward clinical development with reliable GMP manufacturing support.
Coming soon.
No audio URL on this item yet — add one in data-audio.